An observational study in Neuroblastoma, sponsored by Power Life Sciences Inc.. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-26.
Sponsored by Power Life Sciences Inc. · Observational
Historically, participation in clinical research is highly skewed towards particular demographic groups of people.
This study will invite several participants to gather a wide range of information on clinical trial experiences for neuroblastoma patients. The aim of the study is to identify the factors that limit the ability of a person to enroll in, as well as complete a clinical trial for treatment of neuroblastoma.
The data collected from this study will help improve future outcomes for all neuroblastoma patients as well as those in under-represented demographic groups.
625 studies on the registry are indexed under Neuroblastoma; 122 are open to participants now.
This study's planned enrollment of 500 is above the median of 121 across 77 observational studies indexed under Neuroblastoma.
Browse Neuroblastoma studies →Power Life Sciences Inc. is the lead sponsor of 108 studies on the registry; 107 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with neuroblastoma who are actively considering enrolling in an interventional clinical trial for said condition, but have not yet completed enrollment and randomization phases in said clinical trial.
Exclusion Criteria:
Number of patients who decide to enroll in a neuroblastoma clinical trial
Time frame: 3 months
Rate of patients who remain in neuroblastoma clinical trial to trial completion
Time frame: 12 months
Documents are hosted by the registry — open the source record to download them.
Plan to share: Undecided
This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Power Life Sciences Inc.